Steadfast’s ₹100 Cr Bet on India’s Nutraceutical Future

Steadfast has commissioned a fully integrated Formulation Research and Development (FR&D) center, high-capacity nutraceutical manufacturing plant, and advanced quality control laboratory in Noida with an investment exceeding ₹100 crore. Designed to boost domestic manufacturing and curb India's reliance on imported supplements, the WHO-GMP-compliant and FSSAI-licensed facility features high-level automation and stringent multi-stage testing to guarantee product purity. With the QC laboratory currently undergoing NABL accreditation, the plant boasts an annual production capacity of 900 million tablets, 900 million effervescent tablets, 130 million capsules, and 6,500 tonnes of powder.

News by Rahul Yelligetti.